ClinicalTrials.gg
Active, not recruitingNCT06569823Updated Oct 16, 2026

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

A Phase 1/2 interventional study of Z-1018 and Shingrix in Shingles, Herpes Zoster and Vaccine-Preventable Diseases, sponsored by Dynavax Technologies Corporation. Active, not recruiting at 16 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1/2, Interventional, and Prevention

Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
764
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Planned enrollment
14th of 46
764 · median 239
Started
2024
with 2 others
Phase 1/2
2 of 46
1 open now
Primary completion
2027-06
later than 5 of 10 live
Registered
43rd of 46
by date
Lead sponsor
1 of 46
Dynavax Technologies Corporation

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 14th largest by planned enrollment, is one of 3 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 5 of the 10 other live ones, and was the 43rd registered.

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.

Read the detailed description

Part 1 will enroll approximately 440 participants 50 through 69 years of age (YOA) [inclusive] to 1 of 10 arms of Z-1018 or to Shingrix.

Part 2 will enroll approximately 324 participants ≥ 70 YOA to 1 arm of Z-1018 (selected from Part 1) to be administered in a 1:1 randomization ratio with Shingrix.

03

Conditions studied

  • Shingles
  • Herpes Zoster
  • Vaccine-Preventable Diseases
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to participate; provided for the study
  2. Male or female ≥ 50 years of age (Part 1: 50 through 69 years of age, inclusive; Part 2: ≥ 70 years of age
  3. In good health in the opinion of the investigator, based upon medical history, physical examination, and laboratory evaluation
  4. Able to comprehend and follow all required trial procedures and be available for all visits scheduled in the trial
  5. Seronegative for (HIV), virus (HBV), and virus (HCV) as assessed during Screening
  6. If female of and heterosexually active, has practiced adequate for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through 3 months following the final study injection.

Exclusion criteria

Exclusion Criteria:

  1. History of HZ
  2. Previous vaccination against varicella (chicken pox) or HZ
  3. Febrile illness within 7 days of the first trial injection (defined as at least 1 measured body temperature of ≥ 38°C, regardless of route of measurement)
  4. Confirmed SARS-CoV-2/COVID-19 infection as assessed during Screening within 7 days of first trial injection.
  5. If female of , is pregnant (known before or established at the time of screening), breastfeeding, or planning a pregnancy or to breastfeed
  6. Known or suspected immunodeficiency (including but not limited to /AIDS), or state, as assessed by medical history, past or current laboratory studies, and/or physical examination
  7. History of sensitivity to any component of the trial vaccines
  8. Has received the following prior to Day 1 trial injection:

    a) ≤ 14 days: i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG)

    b) ≤ 28 days: i) Any ii) Systemic (≥ 20 mg/ day of prednisone or equivalent for more than 14 consecutive days) or other immunomodulators or immune suppressive medication, with the exception of inhaled steroids iii) Any medicinal agent

    c) ≤ 90 days: i) Granulocyte or granulocyte-macrophage colony-stimulating factor ii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by-case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor) iii) Antisense oligonucleotides iv) Drugs/investigational agents with very long half-lives (defined as ≥ 60 days) (eg, radioactive iodine-125, amiodarone, nirsevimab, and evinacumab) v) Infusion of blood products

    d) ≤ 6 months before Day 1 (or likely to require during the trial period): i) chronic administration of immunosuppressants or other immune-modifying drugs

    e) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells

  9. Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; and/or has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
  10. History or current evidence of any condition, therapy, laboratory abnormality, or other finding that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  11. Underlying chronic medical condition requiring ongoing follow-up and monitoring by a healthcare provider that might affect the immune response to vaccine (eg, diabetes mellitus, chronic kidney disease)
  12. Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
  13. Current or historical disease
  14. Any skin condition and/or tattoo on both arms that may interfere with the evaluation of safety at the injection site, in the opinion of the treating investigator
  15. Any other finding that the Investigator considers will make the participant unsuitable for the trial or unable to comply with the trial requirements
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
764 participants (estimated)

Study arms

  • Experimental
    Z-1018 A1 (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.

    Biological: Z-1018

  • Experimental
    Z-1018 A2 (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.

    Biological: Z-1018

  • Experimental
    Z-1018 B1(a) (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.

    Biological: Z-1018

  • Experimental
    Z-1018 B2(a) (Part 1 and Part 2)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.

    Biological: Z-1018

  • Experimental
    Z-1018 B1(b) (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85

    Biological: Z-1018

  • Experimental
    Z-1018 B2(b) (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85

    Biological: Z-1018

  • Experimental
    Z-1018 Formulation C1(a) (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.

    Biological: Z-1018

  • Experimental
    Z-1018 Formulation C2(a) (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 57.

    Biological: Z-1018

  • Experimental
    Z-1018 Formulation C1(b) (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.

    Biological: Z-1018

  • Experimental
    Z-1018 Formulation C2(b) (Part 1)

    Participants will receive a dose of Z-1018 by intramuscular (IM) injection on Day 1 and Day 85.

    Biological: Z-1018

  • Experimental
    Shingrix (Part 1 and Part 2)

    Participants will receive a dose of Shingrix by intramuscular (IM) injection on Day 1 and Day 57, or Day 1 and Day 85.

    Biological: Shingrix

Interventions

  • BiologicalZ-1018

    Formulation for injection

  • BiologicalShingrix

    Formulation for injection

06

What researchers measure

Primary outcomes

  1. Part 1 and Part 2: Percentage of participants with solicited local and systemic post-injection reactions (PIRs)

    Solicited local and systemic post-injection reactions (PIRs)

    Time frame: Up to 7 days following each dose

  2. Part 1 and Part 2: Percentage of participants with Adverse events (AEs)

    Adverse events (AEs)

    Time frame: 28 days following each dose

  3. Part 1 and Part 2: Percentage of participants with serious adverse events (SAEs), medically-attended adverse events (MAEs), and immune-mediated adverse events of special interest (imAESIs)

    Serious adverse events (SAEs) Medically-attended adverse events (MAEs) Immune-mediated adverse events of special interest (imAESIs)

    Time frame: Day 1 through 12 months after the last dose of study injection

  4. Part 2: Vaccine response

    Composite vaccine response rate in glycoprotein E (gE) -specific CD4+ T cells and anti-gE IgG antibodies in the Per Protocol (PP) population

    Time frame: 4 weeks after the second study injection

  5. Part 2: Anti-gE IgG antibody concentration

    Geometric mean concentration (GMC) and geometric mean ratio of IgG antibodies to varicella-zoster virus (VZV) antigen-gE in the Per Protocol (PP) population

    Time frame: 4 weeks after the second study injection

Secondary outcomes

  1. Part 1: GMC of IgG antibodies to VZV antigen-gE 4 weeks after the second study injection

    GMC to VZV gE in the Per Protocol (PP) population

    Time frame: 4 weeks after the second study injection

  2. Part 1: Geometric mean ratio (GMR) of IgG antibodies to VZV antigen gE

    Geometric mean ratio (GMR) of IgG antibodies to VZV antigen gE in the Per Protocol (PP) population

    Time frame: 4 weeks after the second study injection

  3. Part 1: Geometric mean fold increase (GMFI) of IgG antibodies to VZV antigen gE

    Geometric mean fold increase (GMFI) of IgG antibodies to VZV antigen gE in the Per Protocol (PP) population

    Time frame: 4 weeks after the second study injection

  4. Part 1 and Part 2: Vaccine response rate (VRR) for anti-gE IgG antibodies to VZV antigen gE

    Vaccine response rate (VRR) for anti-gE IgG antibodies to VZV antigen gE in the Per Protocol (PP) population

    Time frame: 4 weeks after the second study injection

  5. Part 2: VRR for gE-specific CD4+ T cells

    VRR for gE-specific CD4+ T cells in the Per Protocol (PP) population

    Time frame: 4 weeks after second study injection

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Nov 2027 → Jun 2027 and completion Nov 2031 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Aug 26, 2024
StartActual
Jun 17, 2024
Primary completionEst.
Jun 2027was Nov 2027
CompletionEst.
Jun 2027was Nov 2031
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2027→Jun 2027
Oct 16, 2026
Study completion
Nov 2031→Jun 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Nov 2027→Jun 2027
    Study completion Nov 2031→Jun 2027
    + 4 other changes: identifiers, verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06569823
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Jun 17, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion